Raloxifene detailed information

Jump to: navigation, search


Raloxifene detailed information
Raloxifene.png
Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]
Pregnancy
category
  • AU: X (High risk)
  • US: X (Contraindicated)
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability2%
Protein binding95%
MetabolismHepatic glucuronidation
CYP system not involved
Elimination half-life27.7 hours
ExcretionFecal
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC28H27NO4S
Molar mass473.584 g/mol

WikiDoc Resources for Raloxifene detailed information

Articles

Most recent articles on Raloxifene detailed information

Most cited articles on Raloxifene detailed information

Review articles on Raloxifene detailed information

Articles on Raloxifene detailed information in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Raloxifene detailed information

Images of Raloxifene detailed information

Photos of Raloxifene detailed information

Podcasts & MP3s on Raloxifene detailed information

Videos on Raloxifene detailed information

Evidence Based Medicine

Cochrane Collaboration on Raloxifene detailed information

Bandolier on Raloxifene detailed information

TRIP on Raloxifene detailed information

Clinical Trials

Ongoing Trials on Raloxifene detailed information at Clinical Trials.gov

Trial results on Raloxifene detailed information

Clinical Trials on Raloxifene detailed information at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Raloxifene detailed information

NICE Guidance on Raloxifene detailed information

NHS PRODIGY Guidance

FDA on Raloxifene detailed information

CDC on Raloxifene detailed information

Books

Books on Raloxifene detailed information

News

Raloxifene detailed information in the news

Be alerted to news on Raloxifene detailed information

News trends on Raloxifene detailed information

Commentary

Blogs on Raloxifene detailed information

Definitions

Definitions of Raloxifene detailed information

Patient Resources / Community

Patient resources on Raloxifene detailed information

Discussion groups on Raloxifene detailed information

Patient Handouts on Raloxifene detailed information

Directions to Hospitals Treating Raloxifene detailed information

Risk calculators and risk factors for Raloxifene detailed information

Healthcare Provider Resources

Symptoms of Raloxifene detailed information

Causes & Risk Factors for Raloxifene detailed information

Diagnostic studies for Raloxifene detailed information

Treatment of Raloxifene detailed information

Continuing Medical Education (CME)

CME Programs on Raloxifene detailed information

International

Raloxifene detailed information en Espanol

Raloxifene detailed information en Francais

Business

Raloxifene detailed information in the Marketplace

Patents on Raloxifene detailed information

Experimental / Informatics

List of terms related to Raloxifene detailed information

Raloxifene is an oral selective estrogen receptor modulator which is used in the prevention of osteoporosis in postmenopausal women. It was announced on April 17, 2006, that raloxifene is as effective as tamoxifen in reducing the incidence of breast cancer in certain high risk groups of females, [1] though with a reduced risk of thromboembolic events and cataracts in patients taking raloxifene versus those taking tamoxifen.[1] On September 14, 2007, the U.S. Food and Drug Administration announced approval of raloxifene for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.[2]

There has been criticism in the mainstream oncology press of the way that information about the drug was released.[3] There has been some confusion in the lay media about the meaning of the trial results. There is no specific clinical evidence for the use of raloxifene in the adjuvant treatment of breast cancer over established drugs such as tamoxifen or anastrozole.[citation needed]

Raloxifene is produced by Eli Lilly Pharmaceuticals and is sold under the brand name Evista®.

Description

Raloxifene hydrochloride (HCl) has the empirical formula C28H27NO4S•HCl, which corresponds to a molecular weight of 510.05 g/mol. Raloxifene HCl is an off-white to pale-yellow solid that is slightly soluble in water.

SERMs mimic estrogen in some tissues and have anti-estrogen activity in others. Other SERMs, such as Pfizer's lasofoxifene and Wyeth's bazedoxifene are in the late

Indication

Raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women, for reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis, and for reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer.

For either osteoporosis treatment or prevention, supplemental calcium and/or vitamin D should be added to the diet if daily intake is inadequate.

Contraindications and precautions

Raloxifene is contraindicated in lactating women or women who are or may become pregnant, in women with active or past history of venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis and in women known to be hypersensitive to raloxifene.

Adverse reactions

Common adverse events considered to be drug-related were hot flashes and leg cramps.

Raloxifene may infrequently cause serious blood clots to form in the legs, lungs, or eyes. Other reactions experienced include leg swelling/pain, trouble breathing, chest pain, vision changes.

As cancer drug

Raloxifene reduces the risk of hormone-positive breast cancer and vertebral fractures "without a shadow of a doubt," but its effects on cardiovascular disease remain less certain, according to the results of the "Raloxifene for Use of the Heart" (RUTH) study published in the July 13, 2006 issue of the New England Journal of Medicine by Dr. Elizabeth Barrett-Connor (University of California at San Diego) and colleagues.[4]

In the trial, in women with coronary heart disease (CHD) or multiple risk factors for CHD, raloxifene had no significant effect on the primary end point, coronary events, but it did significantly increase the risk of venous thromboembolism (VTE). And although the drug had no effect on stroke, there was a seemingly paradoxical significant increase in death from stroke.[5]

On September 14, 2007, Steven Galson, director of the United States Food and Drug Administration's Center for Drug Evaluation and Research announced authorization of the sale of raloxifene to prevent invasive breast cancer in post-menopausal women.[6]

References

  1. Vogel, Victor. "Effects of Tamoxifen vs. Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes". The Journal of the American Medical Association. 295 (23): 2727–2741. Unknown parameter |coauthors= ignored (help)
  2. "FDA Approves New Uses for Evista" (Press release). U.S. Food and Drug Administration. 2007-09-14. Retrieved 2007-09-15.
  3. "A STARring role for raloxifene?". Lancet Oncol. 7 (6): 443. 2006. PMID 16750489.
  4. Lisa Nainggolan (July 12, 2006). "A balancing act: The pro and cons of raloxefene".
  5. Barrett-Connor E, Mosca L, Collins P; et al. (2006). "Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women". New England Journal of Medicine. 355: 125–137.
  6. AFP.google.com, US approves Lilly's Evista for breast cancer prevention
  • Heringa M (2003). "Review on raloxifene: profile of a selective estrogen receptor modulator". Int J Clin Pharmacol Ther. 41 (8): 331–45. PMID 12940590.
  • Barrett-Connor E. "Raloxifene: risks and benefits". Ann N Y Acad Sci. 949: 295–303. PMID 11795366.

External links

hu:Raloxifen



Linked-in.jpg